MDMA Successfully Treats PTSD in Another Phase 3 Trial Sponsored by MAPS
“MDMA-assisted therapy for PTSD is on track to be considered for approval by the FDA in 2024,” says MAPS founder and president Rick Doblin.
Day: September 14, 2023
The Millennium’s Primer Series: Neuroinflammation as a Barrier to the Success of Psychedelic-Assisted Therapies
Initial clinical trials into this exciting frontier have unveiled promising outcomes, showcasing remarkable improvements in clinical results using anti-inflammatory, nanoliposomal products prior to the application of a psychedelic agent.
End of content
End of content